The bone-marrow niche in MDS and MGUS: implications for AML and MM

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Nature Reviews Clinical Oncology

• Publication date

  2018-01-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrclinonc.2017.197PMID 29311715
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A national population-based cohort study to investigate inequalities in maternal mortality in the UK 2009-17

  2020cited by this paper
• Proteomic characterization of human multiple myeloma bone marrow extracellular matrix

  2017cited by this paper
• Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia

  2017cited by this paper
• Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications

  2017cited by this paper
• Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

  2017cited by this paper
• Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.

  2017cited by this paper
• Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.

  2017cited by this paper
• Necroptosis in spontaneously-mutated hematopoietic cells induces autoimmune bone marrow failure in mice

  2017cited by this paper
• A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells

  2017cited by this paper
• Multiple Myeloma and the Immune Microenvironment.

  2017cited by this paper
• Prognostic role of circulating exosomal miRNAs in multiple myeloma.

  2017cited by this paper
• Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

  2017cited by this paper
• Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database

  2017cited by this paper
• Stem and progenitor cell alterations in myelodysplastic syndromes.

  2017cited by this paper
• [Anemia of chronic disease].

  2017cited by this paper
• Haematological cancer: Pembrolizumab is effective in multiple myeloma

  2017cited by this paper
• Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model.

  2017cited by this paper
• Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.

  2017cited by this paper
• Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

  2016cited by this paper
• Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

  2016cited by this paper
• Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model.

  2016cited by this paper
• The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia

  2016cited by this paper
• Extrinsic and Intrinsic Mechanisms by Which Mesenchymal Stem Cells Suppress the Immune System.

  2016cited by this paper
• Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications.

  2016cited by this paper
• Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network

  2016cited by this paper
• Microenvironment-dependent growth of pre-neoplastic and malignant plasma cells in humanized mice

  2016cited by this paper
• Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.

  2016cited by this paper
• PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

  2016cited by this paper
• Chimeric Antigen Receptor (CAR) therapy for multiple myeloma

  2016cited by this paper
• Next Generation

  2016cited by this paper
• Hematopoietic Stem Cell and Its Bone Marrow Niche.

  2016cited by this paper
• Oxidative stress and hypoxia in normal and leukemic stem cells.

  2016cited by this paper
• Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

  2016cited by this paper
• Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype

  2016cited by this paper
• T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

  2016cited by this paper
• Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

  2016cited by this paper
• Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

  2016cited by this paper
• The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

  2016cited by this paper
• Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

  2016cited by this paper
• Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia.

  2016cited by this paper
• Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins

  2016cited by this paper
• CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia.

  2016cited by this paper
• Targeting vasculogenesis to prevent progression in multiple myeloma

  2016cited by this paper
• Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.

  2015cited by this paper
• A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

  2015cited by this paper
• Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma

  2015cited by this paper
• Normal and leukemic stem cell niches: insights and therapeutic opportunities.

  2015cited by this paper
• Report on the 56th ASH Annual Meeting, San Francisco, 4–9 December 2014

  2015cited by this paper
• Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes*

  2015cited by this paper
• CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.

  2015cited by this paper
• Endothelial Progenitor Cell Dysfunction in Myelodysplastic Syndromes: Possible Contribution of a Defective Vascular Niche to Myelodysplasia12

  2015cited by this paper
• FoxO1-Dependent Induction of Acute Myeloid Leukemia by Osteoblasts in Mice

  2015cited by this paper
• The immunomodulatory function of mesenchymal stem cells: mode of action and pathways

  2015cited by this paper
• Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

  2015cited by this paper
• A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

  2015cited by this paper
• Pathogenesis beyond the cancer clone(s) in multiple myeloma.

  2015cited by this paper
• Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

  2015cited by this paper
• Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

  2015cited by this paper
• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

  2015cited by this paper
• Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

  2015cited by this paper
• The hematopoietic stem cell niche in homeostasis and disease.

  2015cited by this paper
• Bone marrow niche in the myelodysplastic syndromes.

  2015cited by this paper
• The osteoblastic niche in the context of multiple myeloma

  2015cited by this paper
• Targeting the bone marrow microenvironment in multiple myeloma

  2015cited by this paper
• Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma

  2015cited by this paper
• Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma

  2015cited by this paper
• Immunotherapy for multiple myeloma: Current status and future directions.

  2015cited by this paper
• CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

  2014cited by this paper
• Engineered nanomedicine for myeloma and bone microenvironment targeting

  2014cited by this paper
• Mesenchymal stem cells in pathogenesis of myelodysplastic syndromes.

  2014cited by this paper
• Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

  2014cited by this paper
• Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenström Macroglobulinemia

  2014cited by this paper
• Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma

  2014cited by this paper
• An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia

  2014cited by this paper
• Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).

  2014cited by this paper
• SDF-1 inhibition targets the bone marrow niche for cancer therapy.

  2014cited by this paper
• An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin

  2014cited by this paper
• Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model.

  2014cited by this paper
• Age-related clonal hematopoiesis associated with adverse outcomes.

  2014cited by this paper
• Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.

  2014cited by this paper
• A Phase IB multicentre dose‐determination study of BHQ880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events

  2014cited by this paper
• CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes

  2014cited by this paper
• Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies

  2014cited by this paper
• Myelodysplasia is in the niche: novel concepts and emerging therapies

  2014cited by this paper
• Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

  2014cited by this paper
• Leukemogenesis Induced by an Activating β-catenin mutation in Osteoblasts

  2014cited by this paper
• Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.

  2014cited by this paper
• A phase 2, randomized, double‐blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low‐ or intermediate‐1–risk myelodysplastic syndrome

  2014cited by this paper
• Contributions of the host microenvironment to cancer-induced bone disease.

  2014cited by this paper
• Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial.

  2014cited by this paper
• Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.

  2014cited by this paper
• Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells.

  2014cited by this paper
• Role of endothelial progenitor cells in cancer progression.

  2014cited by this paper
• Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.

  2014cited by this paper
• How I treat smoldering multiple myeloma.

  2014cited by this paper
• Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

  2013cited by this paper
• Clinical and biological implications of driver mutations in myelodysplastic syndromes.

  2013cited by this paper
• Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells

  2013cited by this paper

• Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study.

  2026cites this paper
• An unconquered challenge in MDS: review of pathophysiology, clinical manifestations, and management options of MDS with thrombocytopenia

  2025cites this paper
• Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study

  2025cites this paper
• Advances in the study of TIM3 in myelodysplastic syndrome

  2025cites this paper
• CAR-T cell therapy for cancer: current challenges and future directions

  2025cites this paper
• Advances in the role of the IGF signaling system in myelodysplastic syndromes and acute myeloid leukemia

  2025cites this paper
• A Monocyte-Driven Prognostic Model for Multiple Myeloma: Multi-Omics and Machine Learning Insights

  2025cites this paper
• The Role of BCL-2 Expression in Patients with Myelodysplastic Neoplasms

  2025cites this paper
• Individualized dynamic risk assessment and treatment selection for multiple myeloma

  2025cites this paper
• Biomimetic nanoparticles enhanced multiple myeloma treatment by removing chemokine (C-C motif) ligand 3 and synergizing PD-L1 blockade

  2025cites this paper
• Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword

  2025cites this paper
• Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective.

  2024cites this paper
• Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy

  2024cites this paper
• Treatment of lower-risk myelodysplastic syndromes

  2024cites this paper
• New horizons in our understanding of precursor multiple myeloma and early interception

  2024cites this paper
• In vitro models of the crosstalk between multiple myeloma and stromal cells recapitulate the mild NF-κB activation observed in vivo

  2024cites this paper
• Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells

  2024cites this paper
• Changes in the intestinal microbiota of multiple myeloma patients living in high‑altitude and cold regions analyzed using 16s rRNA high‑throughput sequencing

  2024cites this paper
• Dual role of signaling pathways in myeloma requires cell type–specific targeting of ligand-receptor interactions

  2024cites this paper
• Enhanced Precision Therapy of Multiple Myeloma through Engineered Biomimetic Nanoparticles with Dual Targeting

  2024cites this paper
• Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model

  2024cites this paper
• Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment

  2023cites this paper
• Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers

  2023cites this paper
• Deep Learning Enables Spatial Mapping of the Mosaic Microenvironment of Myeloma Bone Marrow Trephine Biopsies

  2023cites this paper
• Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapy

  2023cites this paper
• Interleukin-6 Facilitates Acute Myeloid Leukemia Chemoresistance via Mitofusin 1-Mediated Mitochondrial Fusion.

  2023cites this paper
• Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells

  2023cites this paper
• Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies

  2023cites this paper
• Biological research on the occurrence and development of multiple myeloma and its treatment

  2023cites this paper
• Cuproptosis-related lncRNAs forecast the prognosis of acute myeloid leukemia

  2023cites this paper
• The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia.

  2023cites this paper
• Discriminant Principal Component Analysis of ToF‐SIMS Spectra for Deciphering Compositional Differences of MSC‐Secreted Extracellular Matrices

  2023cites this paper
• High Throughput Fluorescence-Based In Vitro Experimental Platform for the Identification of Effective Therapies to Overcome Tumour Microenvironment-Mediated Drug Resistance in AML

  2023influential citation
• Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy

  2023cites this paper
• Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

  2023cites this paper
• The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes

  2023cites this paper
• Metabolic crosstalk between stromal and malignant cells in the bone marrow niche

  2023cites this paper
• A novel prognostic model based on pyroptosis-related genes for multiple myeloma

  2023cites this paper
• Downregulation of stromal syntenin sustains AML development

  2023cites this paper
• Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics

  2023cites this paper
• Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine

  2022cites this paper
• P2X1 enhances leukemogenesis through PBX3-BCAT1 pathways

  2022cites this paper
• Natural Killer Cells in the Malignant Niche of Multiple Myeloma

  2022cites this paper
• β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma

  2022cites this paper
• Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance

  2022cites this paper
• Targeting the Microenvironment for Treating Multiple Myeloma

  2022cites this paper
• Global Proteomics Analysis of Bone Marrow: Establishing Talin-1 and Centrosomal Protein of 55 kDa as Potential Molecular Signatures for Myelodysplastic Syndromes

  2022cites this paper
• TIM3/CEACAM1 pathway involves in myeloid‐derived suppressor cells induced CD8+ T cells exhaustion and bone marrow inflammatory microenvironment in myelodysplastic syndrome

  2022cites this paper
• Monocytosis and Multiple Myeloma: treatment-related acute leukaemia?

  2022influential citation
• Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

  2022cites this paper
• The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma.

  2022cites this paper
• The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape

  2021cites this paper
• Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34+ Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia

  2021cites this paper
• Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy

  2021cites this paper
• The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression

  2021cites this paper
• A syntenin-deficient microenvironment educates AML for aggressiveness

  2021cites this paper
• WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS

  2021cites this paper
• Multiple myeloma

  2021cites this paper
• Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention

  2021cites this paper
• The Therapeutic Potential of Hematopoietic Stem Cells in Bone Regeneration

  2021cites this paper
• Establishment and characterization of HXWMF-1: the first mouse fibroblastic tumor cell line derived from leukemia-associated fibroblasts

  2021cites this paper
• Facts and Hopes in Multiple Myeloma Immunotherapy

  2021cites this paper
• ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment.

  2021cites this paper
• STAT3 is over-activated within CD163pos bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS

  2021cites this paper
• CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma

  2021cites this paper
• Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns

  2021cites this paper
• Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways

  2021cites this paper
• Rationally integrating peptide-induced targeting and multimodal therapies in a dual-shell theranostic platform for orthotopic metastatic spinal tumors.

  2021cites this paper
• Extracellular Vesicles Tell All: how vesicle-mediated cellular communication shapes hematopoietic stem cell biology with increasing age.

  2021cites this paper
• Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected

  2021cites this paper
• Construction of a solid Cox model for AML patients based on multiomics bioinformatic analysis

  2021cites this paper
• The role of macrophages and osteoclasts in the progression of leukemia

  2021cites this paper
• Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features

  2021cites this paper
• Decellularized ECM derived from normal bone involved in the viability and chemo-sensitivity in Multiple myeloma cells.

  2021cites this paper
• How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?

  2021cites this paper
• The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia

  2021cites this paper
• Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy

  2021cites this paper
• Autonomic nervous system control of multiple myeloma.

  2020cites this paper
• Absence of a common founder mutation in patients with co-occurring myelodysplastic syndrome and plasma cell disorder.

  2020cites this paper
• Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy

  2020cites this paper
• Altered Spatial Composition of the Immune Cell Repertoire in the Bone Marrow Stem Cell Niche in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia

  2020cites this paper
• Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins

  2020cites this paper
• The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma

  2020cites this paper
• Characterization of the role of Samsn1 loss in multiple myeloma development

  2020cites this paper
• Bisphosphonates for delivering drugs to bone

  2020cites this paper
• Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma

  2020influential citation
• What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics.

  2020cites this paper
• Cancer immunoediting and immune dysregulation in multiple myeloma.

  2020cites this paper
• Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma

  2020cites this paper
• Summary of the 2019 BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

  2020cites this paper
• A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche

  2020cites this paper
• Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma

  2020cites this paper
• The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies

  2020cites this paper
• A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma

  2020cites this paper
• A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib.

  2020cites this paper
• Second malignancies in multiple myeloma; emerging patterns and future directions.

  2020cites this paper
• Dual oligopeptides modification mediates arsenic trioxide containing nanoparticles to eliminate primitive chronic myeloid leukemia cells inside bone marrow niches.

  2020cites this paper
• Stem cell donors should be screened for CHIP.

  2020cites this paper
• Downregulation of extracellular vesicle microRNA-101 derived from bone marrow mesenchymal stromal cells in myelodysplastic syndrome with disease progression.

  2020influential citation
• Targets of biologic disease‐modifying antirheumatic drugs and risk of multiple myeloma

  2020cites this paper